CJC-1295 DAC and CJC-1295 (Modified GRF 1-29) are both Growth Hormone Releasing Hormones (GHRH). Their action in the human body is identical, but the difference between the two peptides is the span of the half-life. Modified GRF 1-29 and Sermorelin have a very short acting half-life of about 30 minutes, while CJC-1295 DAC has a half-life of up to approximately 8 days. Many scientists have reported that the short half-life of Sermorelin and Modified GRF 1-29 is considered much more natural as they produce a short pulse of Human Growth Hormone.

CJC-1295 DAC is a long-acting growth hormone-releasing hormone, which causes the anterior pituitary gland to release more growth hormone. DAC is an additive moiety that prolongs the plasma half-life of CJC-1295. GHRH is released in pulses in the body, which alternate with corresponding pulses of somatostatin (growth-hormone inhibiting-hormone). The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous HGH are presumed to increase lipolysis (fat loss). The clinical research was ultimately successful for most research subjects. Ghrelin, released from the gut, which circulates and acts as a hunger hormone, has synergistic activity in the body with GHRH and also suppresses somatostatin to make way for the GHRH pulse. Studies show that combining a GHRP-6 with CJC-1295 DAC significantly increases the release of GH and IGF-1 production without an increase in prolactin. CJC-1295 DAC is an exceptionally designed peptide known for being the finest hGH secretogues. The DAC (Drug Affinity Complex) portion increases the half-life by binding with serum albumin, protecting the CJC-1295 DAC peptide from degradation. This was formed when a lysine link was bound to DACs to a reactive chemical called maleimidoproprionic acid (MPA).